The present study examined whether
thrombin activates the
complement cascade in the brain and whether
N-acetylheparin, an inhibitor of complement activation, attenuates
brain injury induced by
thrombin. There were three sets of studies. In the first set, rats had an intracerebral infusion of either five-unit
thrombin or a needle insertion. Brains were sampled at 24 hours for Western blot analysis and immuno-histochemistry. In the second set, rats received either five-unit thrombin+saline, five-unit thrombin+25 microg
N-acetylheparin or five-unit thrombin+100 microg
N-acetylheparin infusion. Brains were sampled 24 hours later for water content measurement. In the third set, rats received either five-unit thrombin+saline or five-unit thrombin+ 100 microg
N-acetylheparin. Behavioral tests sensitive to unilateral striatal damage were carried out for two weeks. Western blotting demonstrated that
complement C9 and
clusterin levels increase 24 hours after
thrombin infusion (P < 0.01). Both C9 and
clusterin positive cells were found around the injection site. High-dose (100-microg) but not low-dose (25-microg)
N-acetylheparin attenuated
thrombin-induced
brain edema (81.5 +/- 0.4% vs. 83.7 +/- 0.3% in the vehicle, P < 0.05). Behavior was also significantly improved by
N-acetylheparin (P < 0.05). In conclusion,
thrombin-induced
edema formation and neurological deficits were both reduced by
N-acetylheparin. This suggests that inhibition may be a novel treatment for the
thrombin-induced
brain injury that occurs in
intracerebral hemorrhage.